PATENT CLAIM ANALYSIS

Application Number: 16156608
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-05
Patent Classification: ["514", "265100"]

Abstract:
Provided herein are methods of treating focal segmental glomerulosclerosis, said methods include administering to a subject in need thereof a therapeutically effective amount of a CCR2 antagonist. In some embodiments, the CCR2 antagonist is used in monotherapy. In some embodiments, the CCR2 antagonist is used in combination therapy. In some embodiments, the additional therapeutic agent is a RAAS blocker and/or an endothelin receptor inhibitor.

Claim (Index 28):
The method of  claim 18 , wherein the additional therapeutic agent is an endothelin receptor antagonist.

Metadata:
- Claim Count in Document: 80.0
- Percentile: 97.0
- Lexical Diversity: 1.63636
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13907202', '15233520', '14806174', '15841767', '14043602']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7714113003908888
- 35 USC 102 Novelty (BERT): 0.5107812282327753
- Combined Prediction Score: 0.7453482931750774
- Mean Citation Score: 233.055782
- Max Citation Score: 234.31662000000003
- Similarity Product: 140.66243505651715

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test